Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Clinical Biosimilar'

Clinical Biosimilar published presentations and documents on DocSlides.

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • stefany-barnette
  • 0 Slides

OMIC Group Biosimilars 2014. Hyderabad India. 27-...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • danika-pritchard
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

PhAMA Position on Biosimilar Medicines

PhAMA Position on Biosimilar Medicines

  • celsa-spraggs
  • 0 Slides

Ms. Leah Goodman. Contents. Key Messages. An Over...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • aaron
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • myesha-ticknor
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

Biosimilar Biological Products

Biosimilar Biological Products

  • luanne-stotts
  • 0 Slides

2016 . Clinical Investigator . Training Course. S...

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • calandra-battersby
  • 0 Slides

OMIC Group Biosimilars 2014. Hyderabad India. 27-...

MODULE 8. Follow-on drugs: generic, biosimilar

MODULE 8. Follow-on drugs: generic, biosimilar

  • alida-meadow
  • 0 Slides

& non-biological similar medicinal products ....

U.S. Biosimilars: An Introduction

U.S. Biosimilars: An Introduction

  • calandra-battersby
  • 0 Slides

Disclaimers. :. By 2016, 7 of the top 10 pharmace...

The generic and biosimilar

The generic and biosimilar

  • alida-meadow
  • 0 Slides

perspective. Warwick Smith. Director General BGMA...

Application of Biosimilars in RA IN Clinical Practice:

Application of Biosimilars in RA IN Clinical Practice:

  • conchita-marotz
  • 0 Slides

Key Issues and Challenges.  . Introduction. Diff...

Biosimilars

Biosimilars

  • lindy-dunigan
  • 22 Slides

Knowledge Connect Slide Resource. This slide dec...

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • calandra-battersby
  • 0 Slides

OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...

Biological Products: concepts, naming,

Biological Products: concepts, naming,

  • faustina-dinatale
  • 0 Slides

interchangeability,extrapolation. and safety. Dr...

Faculty Leonard H. Calabrese, DO

Faculty Leonard H. Calabrese, DO

  • trish-goza
  • 0 Slides

Professor of Medicine. Cleveland Clinic Lerner Co...

Acceptable changes in quality attributes of glycosylated bi

Acceptable changes in quality attributes of glycosylated bi

  • debby-jeon
  • 19 Slides

Schiestl M, Stangler T, Torella C, et al. . Nat B...

Biosimilars in RA: A Blessing or a Curse?

Biosimilars in RA: A Blessing or a Curse?

  • conchita-marotz
  • 0 Slides

Introduction/Overview . What Is a Biosimilar?. Di...

Understanding Biologics Biologics and Biosimilars

Understanding Biologics Biologics and Biosimilars

  • calandra-battersby
  • 0 Slides

Animation: What Are Biologics?. Production of Bio...

  What is the value of Real-World Evidence for Biosimilars?

  What is the value of Real-World Evidence for Biosimilars?

  • bitsy
  • 82 Slides

Disclaimer. This panel is moderated by Dr. Delphin...

Category 1: Defining Terms

Category 1: Defining Terms

  • jasmine
  • 76 Slides

Clue: . A biologic product with no clinically mean...

Biosimilars in the united states – Update on FDA Impleme

Biosimilars in the united states – Update on FDA Impleme

  • test
  • 37 Slides

James C. Shehan. Hyman, Phelps & McNamara, P....

What You Need to Know About

What You Need to Know About

  • marina-yarberry
  • 17 Slides

Biosimilars. : Products, Recent Deals, IP Issues ...

Is Australia ready for

Is Australia ready for

  • liane-varnes
  • 12 Slides

biosimilar. . ?. David Lim, Julie Hepworth, Lis...

Phil Johnson MS

Phil Johnson MS

  • stefany-barnette
  • 56 Slides

RPh. Safe School Meds, Principle Partner. Moffitt...

Concurrent Session 1B

Concurrent Session 1B

  • yoshiko-marsland
  • 0 Slides

View . from the Life Sciences . Industry. Moderat...

US Regulatory Pathway For Biosimilars

US Regulatory Pathway For Biosimilars

  • cheryl-pisano
  • 0 Slides

Practical Legal/Regulatory Considerations Arising...

Biosimilars in the Real World

Biosimilars in the Real World

  • liane-varnes
  • 0 Slides

Introduction/Overview . PLANETRA Extension Study:...

Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives

Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives

  • alida-meadow
  • 0 Slides

Richard Montes, Ph.D.. Hospira. , a Pfizer compan...

Applying Biosimilars in Hematologic Cancers

Applying Biosimilars in Hematologic Cancers

  • conchita-marotz
  • 0 Slides

This program will include a discussion of off-lab...

United Spinal Association

United Spinal Association

  • alida-meadow
  • 0 Slides

August, 2014. Biologics & Biosimilars: . An O...

Phil Johnson MS RPh Safe School Meds, Principle Partner

Phil Johnson MS RPh Safe School Meds, Principle Partner

  • yoshiko-marsland
  • 0 Slides

Moffitt Cancer Center, Director of Pharmacy (Reti...

22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum

22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum

  • carla
  • 9 Slides

Adoption by CHMP for release for consultation24 Ma...

INSIGHTS INTO THE MARKET

INSIGHTS INTO THE MARKET

  • summer
  • 20 Slides

FOR INFLIXIMABTable of ContentsThe Evolving Landsc...

Budget impact and cost-effectiveness of oncology

Budget impact and cost-effectiveness of oncology

  • roxanne
  • 14 Slides

biosimilars. Prof. dr. Steven Simoens. Health econ...

JMP for Biosimilars : Tools for Analytical Similarity

JMP for Biosimilars : Tools for Analytical Similarity

  • erica
  • 26 Slides

Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...

Biosimilars in emerging markets- regulatory and Commercial considerations

Biosimilars in emerging markets- regulatory and Commercial considerations

  • jane-oiler
  • 0 Slides

OMIC Group. Biosimilars 2104. Hyderabad. India. 2...

1 Immunogenicity The key safety issue for biosimilars

1 Immunogenicity The key safety issue for biosimilars

  • gelbero
  • 29 Slides

Prof. Ibrahim A. . Alsarra. Professor . of . Phar...

Challenges in Assessing Therapeutic Equivalence of

Challenges in Assessing Therapeutic Equivalence of

  • thomas
  • 27 Slides

Nanosimilars. Beat . Flühmann. Global Lead NBCD ....

Biosimilars & EU regulation

Biosimilars & EU regulation

  • karlyn-bohler
  • 0 Slides

Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...

NEUPOGEN filgrastim

NEUPOGEN filgrastim

  • gelbero
  • 5 Slides

GRANIX (tbo - filgrastim), NIVESTYM (filgrastim -...

Copyright © 2024 DocSlides. All Rights Reserved